iCP-NI - Safety, Tolerability, Pharmacokinetic, and Immunogenicity Study in Healthy Male and Female Subjects

Phase 1 Terminated 24 enrolled Cellivery Therapeutics, Inc. Labcorp Corporation of America Holdings, Inc · collab

RandomizedSequentialDouble-blindTreatment

Summary

This is a Phase 1, double-blind, randomized, placebo-controlled study to investigate single and multiple intravenous infusions of improved cell-permeable nuclear import inhibitor (iCP NI) in healthy subjects.

Timeline

Start: 2023-01-19
Primary completion: 2023-04-20
Completion: 2023-04-20

Outcome

Outcome not reported

Stopped (Business): “Closed by Sponsor for business reasons”

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	iCP-NI	Peptide	20 mg/ml	Intravenous

Indications

No indication recorded.